19 Oct 2026

Dutasteride vs Finasteride: Which Hair Loss Treatment Is Better?

Compare effectiveness, side effects, FDA status, and key tradeoffs to understand which hair loss treatment may fit your needs. Explore the evidence.

Share

TL;DR

In the dutasteride vs finasteride debate, dutasteride often produces greater average improvements in hair measurements because it blocks more of the pathway that produces dihydrotestosterone (DHT). That does not make it the right choice for everyone. Finasteride is FDA-approved for male pattern hair loss, clears from the body more quickly, and remains a practical first option for many men. Dutasteride is an off-label alternative that warrants a more individualized discussion about benefits, side effects, fertility, and its prolonged persistence in the body. Both require medical oversight.

Table of Contents

Dutasteride vs Finasteride for Hair Loss: The Short Answer

Dutasteride vs Finasteride for Hair Loss: The Short Answer

After comparing Reddit photos and reading conflicting side-effect stories, many people still do not know whether dutasteride is a sensible upgrade or unnecessary overkill. Our direct view is this: dutasteride suppresses DHT more broadly and often performs better on average hair measurements, but stronger is not automatically better for each patient.

Oral finasteride 1 mg is FDA-approved for male pattern hair loss in men in the United States. Dutasteride is FDA-approved for benign prostatic hyperplasia, not hair loss, so prescribing it for androgenetic alopecia in the U.S. is off-label.

Off-label does not mean ineffective or inappropriate. It means the prescribing decision requires clinical judgment. The potential benefit must be weighed against dutasteride’s prolonged persistence, individual tolerability, reproductive plans, treatment history, and the less standardized nature of off-label dosing schedules.

Comparison Finasteride Dutasteride
Average efficacy Can slow progression and support maintenance or regrowth Often produces greater average improvements in comparative studies
Mechanism Primarily inhibits type II 5-alpha-reductase Inhibits type I and type II 5-alpha-reductase
U.S. hair-loss approval Oral 1 mg is FDA-approved for male pattern hair loss in men Not FDA-approved for hair loss; use is off-label
Commonly studied oral regimen 1 mg daily for male pattern hair loss Studies have examined several doses, including 0.5 mg daily
Persistence in the body Clears relatively quickly Has a much longer half-life and can remain in the body after treatment stops
Oral evidence Extensive clinical use and a well-established role in treatment Favorable comparative efficacy evidence, with less long-term hair-loss experience
Topical evidence More developed, although formulas and doses vary More limited and highly dependent on formulation
Safety considerations Sexual, mood, breast, semen, fertility, pregnancy-exposure, allergy, and PSA considerations Similar categories, with prolonged exposure adding a practical concern
Cost Varies by country, insurance, pharmacy, brand, and dose Varies by country, insurance, pharmacy, off-label access, and formulation
Universal winner? No No

Neither medication cures androgenetic alopecia. Both work on susceptible follicles that are still capable of responding, and maintained benefits generally depend on continued treatment.

Stopping treatment may allow DHT-driven miniaturization to resume. The goal is therefore not simply to achieve short-term regrowth. It is to find a medically appropriate plan that remains tolerable, affordable, and sustainable.

The Decision in One Sentence

Choose between dutasteride and finasteride by considering expected benefit, regulatory status, reversibility, diagnosis, previous response, health history, reproductive plans, and personal priorities—not DHT suppression alone.

A treatment-naive man with typical androgenetic alopecia may reasonably discuss approved finasteride first. Someone with documented progression despite an adequate and consistent trial may have a stronger reason to discuss off-label dutasteride or a broader treatment strategy.

Finasteride and Dutasteride Side by Side

Head-to-head research generally supports greater average hair improvement with dutasteride than with finasteride 1 mg. It does not prove that every individual will grow more hair, tolerate dutasteride well, or consider the difference worthwhile.

Finasteride has the practical advantages of FDA approval for male pattern hair loss, extensive treatment experience, and faster clearance. Dutasteride offers broader enzyme inhibition and potentially greater efficacy, but stopping it does not rapidly end exposure.

The clearest comparative finding concerns average efficacy. The less certain questions involve long-term individual tolerability, persistent symptoms, the best off-label schedule, and which patient characteristics reliably predict a better personal response.

How Finasteride and Dutasteride Block DHT

The enzymes known as 5-alpha-reductase convert testosterone into dihydrotestosterone, or DHT. In genetically susceptible scalp follicles, DHT contributes to progressive miniaturization. Each growth cycle may produce a shorter, finer hair until visible density declines.

Finasteride primarily inhibits type II 5-alpha-reductase. Dutasteride inhibits both type I and type II, creating broader enzyme blockade and greater average suppression of circulating DHT.

That difference is why dutasteride is often called stronger. Serum DHT is not a complete scorecard for scalp response, however. The lowest laboratory value does not automatically produce the best visible result or the most suitable long-term treatment.

Both medications act on existing follicles. They cannot create unlimited new follicles, reliably restore every long-inactive follicle, or treat unrelated causes of hair loss. Nutritional, endocrine, inflammatory, medication-related, and scarring conditions may require a different approach.

Why More DHT Suppression Can Improve Efficacy

Broader enzyme inhibition reduces the androgen signal involved in miniaturization. This creates a reasonable biological basis for dutasteride to preserve more susceptible follicles or produce greater average improvements in density and hair thickness.

Comparative clinical findings broadly support that explanation. A 2024 systematic review of finasteride and dutasteride reported stronger regrowth and miniaturization-related outcomes with dutasteride across much of the included evidence. The review also included studies with different designs, populations, doses, and methods, so its findings should not be treated as a guarantee for every patient.

Mechanism is only part of the outcome. Disease stage, follicular sensitivity, adherence, treatment duration, dose, scalp health, and concurrent therapies can all influence what appears in the mirror.

Why Genetics and Diagnosis Still Matter

Two people with similar recession can respond differently because their androgen sensitivity, hair-loss pattern, disease duration, and remaining follicular reserve differ. Someone with diffuse shedding caused by another condition may gain little from escalating DHT suppression before the underlying diagnosis is addressed.

Genetic information can add context, but no responsible test can guarantee that finasteride or dutasteride will work without side effects. We view the HairOS™ Genetic Test as one input alongside clinical diagnosis, medical history, examination, treatment response, and individual priorities.

Personalization should reduce blind trial and error, not hide uncertainty. Better decisions come from gathering better evidence about the person, the diagnosis, and the treatment response.

Which Works Better? Comparing Hair Count, Density, and Miniaturization

Which Works Better? Comparing Hair Count, Density, and Miniaturization

When researchers compare dutasteride and finasteride in controlled studies, dutasteride often performs better on average hair-count or photographic assessments. Systematic reviews reach a similar overall conclusion while noting meaningful differences among the underlying studies.

This is group-level evidence. It cannot tell one person whether the visible difference will be dramatic, modest, or impossible to notice without standardized measurements.

The meaning of “works” also needs clarification. Hair-loss studies may assess several related but distinct outcomes:

  • Stabilization: Progression slows or stops.
  • Reduced shedding: Fewer hairs are noticed during washing or styling.
  • Increased hair count: More hairs are measured within a defined scalp area.
  • Improved density: Less scalp is visible under standardized conditions.
  • Shaft thickening: Miniaturized hairs become wider and provide more coverage.
  • Reversal of miniaturization: Susceptible follicles produce more substantial hairs.
  • Photographic improvement: Assessors judge the overall appearance as improved.

A medication can preserve hair without producing dramatic regrowth. Because androgenetic alopecia is progressive, maintaining current density may still be a meaningful result.

The evidence has limitations. Studies vary in dose, duration, participant characteristics, baseline severity, photography, hair-count methods, and concurrent treatments. Long-term head-to-head safety evidence is also less extensive than short-term comparative efficacy evidence, which matters for medication that may be taken for years.

Female pattern hair loss requires a separate discussion. Pregnancy risk, hormonal context, menopausal status, possible alternative diagnoses, and the available evidence all affect treatment decisions. Findings from studies in men should not automatically be applied to women.

What Head-to-Head Studies Suggest

Controlled comparisons deserve more weight than dramatic before-and-after photos. Researchers can define endpoints, monitor treatment, compare groups, and use more consistent assessment methods.

Across that evidence, dutasteride usually has the advantage in average efficacy. Finasteride remains clinically useful because a smaller average effect is not the same as an inadequate individual result.

Research also cannot promise durable benefit or tolerability for a particular person. A statistically better average does not settle questions about side effects, affordability, adherence, or whether the additional visible improvement will matter to that patient.

Who May See Less Regrowth Than Expected

Results may be limited when substantial follicular loss has already occurred. Earlier treatment generally leaves more viable follicles to preserve than treatment started after advanced miniaturization.

Other reasons for disappointing results include:

  • The original diagnosis was incomplete or incorrect.
  • Treatment was used inconsistently.
  • Follow-up was too short.
  • Regrowth was expected when stabilization was the more realistic goal.
  • Scalp inflammation or another hair-loss condition remains untreated.
  • Nutritional, endocrine, medication-related, or health factors are contributing.
  • Photographs differ in lighting, angle, hair length, styling, or distance.
  • Several treatments began together, making their individual effects unclear.

More DHT suppression will not correct each of these problems. Before escalating treatment, we recommend checking the diagnosis and confirming with consistent evidence that the existing plan has actually failed.

Doses, Schedules, and FDA Approval: What Is Established vs Off-Label

Oral finasteride 1 mg daily is FDA-approved for male pattern hair loss in men. Oral dutasteride is not FDA-approved for hair loss in the United States, although it has been studied for androgenetic alopecia and is prescribed off-label in some cases.

Clinical research has examined finasteride 1 mg daily and several dutasteride doses, including 0.5 mg daily. These study regimens describe the evidence. They are not universal prescribing instructions.

Dutasteride’s long half-life has prompted online discussion of weekly or intermittent use. The pharmacological reasoning may sound persuasive, but internet-popular schedules should not be treated as validated do-it-yourself protocols.

Self-directed stacking, alternating, or switching can create overlapping exposure. It also makes it harder to determine which drug caused a benefit or unwanted effect, particularly when dutasteride remains in the body long after the last dose.

Daily Versus Intermittent Dutasteride

Because dutasteride accumulates and clears slowly, its effects are not confined to the day a capsule is taken. Clinicians and researchers have therefore considered schedules other than daily use.

The evidence for intermittent schedules is less standardized than online discussions often suggest. A suitable approach may depend on previous treatment, health status, goals, tolerability, other medications, and the prescriber’s monitoring plan.

We do not recommend copying a weekly protocol from Reddit or changing frequency in response to a temporary shed. Dose and schedule decisions belong with the clinician responsible for assessing both benefit and risk.

Hair-Loss Treatment Versus BPH Treatment

Finasteride and dutasteride are also used for benign prostatic hyperplasia, or BPH. The indication, dose, typical patient, treatment goal, and monitoring requirements may differ from those involved in hair-loss care.

Higher-dose finasteride is associated with BPH treatment, while dutasteride’s FDA-approved use is for BPH rather than hair loss. A regimen used for one condition should not automatically be transferred to the other.

Both medications can affect prostate-specific antigen, or PSA, results. Anyone taking either drug should tell the clinician ordering or interpreting a PSA test.

Dutasteride vs Finasteride Side Effects and Long-Term Risks

Finasteride and dutasteride affect the same hormonal pathway, so their potential adverse effects overlap. Reported concerns include:

  • Decreased libido
  • Erectile or ejaculatory changes
  • Reduced semen volume
  • Changes in semen parameters
  • Breast tenderness or enlargement
  • Mood symptoms
  • Allergic reactions

Reported rates vary by dose, treatment duration, study design, population, follow-up, and how symptoms are collected. Comparative data cannot predict with certainty whether one person will experience an adverse effect or tolerate one drug better than the other.

Some patients report sexual, neurological, or mood-related symptoms that continue after stopping finasteride. These reports should not be dismissed, but questions remain about incidence, mechanisms, risk factors, and causality.

Dutasteride adds a practical concern: stopping treatment does not quickly end exposure. Its long half-life means it can remain in the body for an extended period, which matters when a patient develops a troubling symptom or is planning conception.

Both medications may affect semen characteristics in some men. Anyone trying to conceive, experiencing fertility problems, or undergoing fertility treatment should discuss timing, alternatives, evaluation, and monitoring with a qualified clinician.

People who are pregnant or may become pregnant should not handle crushed or broken tablets because of potential exposure to a male fetus. Topical products also require precautions because medication can be transferred through hands, spills, surfaces, or skin contact before the application site dries.

Severe mood changes, suicidal thoughts, signs of a serious allergic reaction, breast lumps or discharge, and significant testicular pain require prompt medical assessment.

Does Dutasteride Have Worse Side Effects?

Not necessarily for every person. Dutasteride suppresses DHT more broadly and persists longer, giving it a different risk-benefit profile. Available evidence does not support claiming that everyone will experience more frequent or severe side effects.

Reported adverse-effect rates may be influenced by:

  • Dose and treatment duration
  • Baseline sexual and mental health
  • Age and other health conditions
  • Concurrent medications
  • How researchers ask about symptoms
  • Expectations and nocebo effects
  • Loss to follow-up
  • Length of monitoring

The useful question is not which drug has the more alarming list. It is which risks matter most to the individual, how much reversibility they want, which symptoms exist at baseline, and how treatment will be monitored.

Why Half-Life Changes the Conversation

Finasteride’s plasma half-life is measured in hours, while dutasteride has a much longer terminal half-life and may remain measurable for months after discontinuation.

This does not mean finasteride’s effect on hair disappears within hours. It means the circulating drug clears more quickly, providing greater pharmacological reversibility if treatment must stop.

Dutasteride does not offer the same immediate off switch. That distinction deserves as much attention as its stronger DHT suppression, particularly when fertility, tolerability, medication changes, or other health circumstances are a concern.

Mood, Fertility, Breast, and Pregnancy Considerations

A useful clinical discussion should establish baseline symptoms before treatment begins. Without a baseline, separating a new medication-related change from a pre-existing or unrelated problem can be difficult.

Topics to discuss include:

  • Current libido, erectile function, and ejaculatory function
  • Depression, anxiety, severe mood symptoms, or suicidal thoughts
  • Fertility plans and any previous fertility assessment
  • Breast tenderness, enlargement, lumps, or discharge
  • Testicular symptoms
  • Current prescriptions and supplements
  • PSA testing or prostate monitoring
  • Pregnant household members or partners who may become pregnant
  • Safe storage and application of topical products

Uncertain causality is not a reason to minimize a concerning symptom. Baseline documentation, timely reporting, and clinical review make the assessment more reliable.

How Long Results Take—and When Finasteride Has Really Failed

A few disappointing months do not necessarily prove that finasteride has failed. Hair growth cycles are slow, and early shedding, fluctuating density, or a lack of obvious visual change can occur before the longer-term trend becomes clear.

Clinicians generally assess progress over several months rather than several weeks. The appropriate review point depends on the diagnosis, treatment, consistency of use, and clinical circumstances.

Before calling treatment ineffective, ask:

  • Was androgenetic alopecia confirmed?
  • Was treatment used consistently?
  • Were the dose and application practices stable?
  • Was the trial long enough to evaluate?
  • Were other treatments started or stopped?
  • Is the shedding sudden, diffuse, inflamed, or otherwise atypical?
  • Could nutritional or endocrine factors be contributing?
  • Is a scalp disorder present?
  • Did another medication or major health event change?
  • Is progression objectively documented?
  • Were expectations focused only on regrowth rather than preservation?

Switching may be reasonable after an adequate trial with documented progression, poor tolerability, or changed treatment goals. It should not be triggered solely by someone else’s dramatic short-term photos.

A Practical Progress-Tracking Plan

Record a baseline date and take standardized photographs of the hairline, temples, mid-scalp, and crown. Keep the lighting, camera, distance, angle, hair length, wetness, parting, and styling as consistent as possible.

Track a focused set of variables:

  • Treatment name, dose, and start date
  • Missed doses or application changes
  • Changes in shedding
  • Scalp symptoms
  • Sexual, mood, breast, or other possible adverse effects
  • Minoxidil and other concurrent treatments
  • Major illness, weight change, or medication changes
  • Follow-up photograph dates

Assess trends rather than isolated photos or day-to-day shedding. Bright overhead lighting and shorter hair can make stable density appear worse, while strategic styling can hide progression.

Before Switching to Dutasteride

First, confirm the diagnosis and check whether another condition is contributing. Stronger DHT suppression will not correct untreated inflammatory scalp disease, telogen effluvium, nutritional deficiency, endocrine disease, or scarring alopecia.

Then discuss:

  • Whether the finasteride trial was adequate
  • Documented progression versus subjective concern
  • Existing side effects
  • Reproductive plans
  • Other medications and health conditions
  • Possible overlap or washout
  • Monitoring expectations
  • Dutasteride’s prolonged persistence
  • Whether combination treatment is more suitable than substitution

There is no universal switching protocol for every patient. Prescription changes require a clinician who can account for accumulated exposure and interpret symptoms over time.

Oral vs Topical Finasteride and Dutasteride

Topical treatment aims to deliver medication to the scalp while limiting systemic exposure. That is a reasonable objective, but topical does not mean free from systemic absorption or side effects.

Topical finasteride can enter the circulation and reduce serum DHT. Systemic exposure from topical dutasteride also cannot be assumed to be zero. The amount absorbed may depend on the formulation, concentration, applied volume, treatment area, skin condition, and frequency.

Topical finasteride has more clinical research than topical dutasteride. Even then, products are not automatically interchangeable because their concentrations, vehicles, applied volumes, ingredient combinations, and manufacturing standards vary.

Many topical hair-loss medications in the U.S. are compounded. Quality controls, stability, dosing consistency, storage requirements, and the source of the active ingredients therefore matter.

A personalized formula may contain several active ingredients, but combinations complicate interpretation. If minoxidil and a DHT-targeting medication begin together, it can be difficult to identify which ingredient caused regrowth, shedding, irritation, or a systemic symptom.

What to Ask About a Topical Formula

Before using a compounded product, ask:

  • What is the finasteride or dutasteride concentration?
  • What volume is applied with each dose?
  • How much active medication does that volume contain?
  • Which vehicle carries the medication?
  • What quality and stability checks are performed?
  • How should the bottle be stored?
  • Does it contain minoxidil or another active ingredient?
  • How long should the scalp dry before contact?
  • Which systemic effects should be monitored?
  • Which pregnancy-exposure precautions are required?

Applied volume matters alongside the percentage printed on the label. A higher concentration used in a smaller volume is not automatically equivalent to a lower concentration applied across a larger area.

The HairOS™ Precision Growth System reflects our preference for matching treatment inputs to individual information rather than giving everyone the same formula. Personalization must still include clear dosing, safety counselling, realistic expectations, and clinical oversight.

Can Topical Treatment Lower Systemic Risk?

Potentially, but any reduction depends on the dose and formulation. A carefully designed topical product may reduce systemic exposure compared with an oral regimen, yet absorption can still occur.

Symptoms and monitoring remain relevant. Users should also wash their hands after application, follow drying instructions, clean spills, store the product securely, and prevent contact with children or anyone who is or may be pregnant.

A topical treatment should be assessed as a specific formula, not as a risk-free category. Concentration, vehicle, dose, application area, skin barrier, and other ingredients all affect exposure.

How to Choose Without Guessing: A Personalized Decision Framework

The right comparison begins with the person rather than a potency ranking. We use a framework that considers:

  1. Diagnosis: Is androgenetic alopecia confirmed?
  2. Pattern and severity: Is loss concentrated at the crown, hairline, or across the scalp?
  3. Rate of progression: Is the change gradual, rapid, or objectively unclear?
  4. Follicular reserve: Is preservation more realistic than substantial regrowth?
  5. Previous treatment: Was finasteride used consistently and for an adequate period?
  6. Tolerability priorities: How important is faster reversibility?
  7. Reproductive plans: Is conception an immediate or future consideration?
  8. Health history: Are sexual, mood, fertility, breast, prostate, or other relevant concerns present?
  9. Other medications: Could interactions or overlapping adverse effects complicate assessment?
  10. Budget: What is the total ongoing cost, including consultations, monitoring, and compounded products?
  11. Monitoring: Will standardized photographs and scheduled reviews be maintained?

Price comparisons vary by country, insurance, pharmacy, dose, brand, and whether the product is compounded. The useful comparison is the complete ongoing cost, not an assumption that one drug is always cheaper.

Genetic and clinical data may help narrow the options, but neither can guarantee efficacy or safety. Our approach at Roots by Genetic Arts combines a documented baseline, evidence-led treatment decisions, and scheduled reassessment.

This article is educational and does not provide a diagnosis or prescription. Medication selection, dosing, switching, combination treatment, and monitoring require an appropriately licensed clinician.

Is Dutasteride Actually Better Than Finasteride?

Dutasteride is often more effective on average in comparative studies. Its inhibition of both type I and type II 5-alpha-reductase offers a clear explanation for that advantage.

Finasteride may still be the more suitable starting option for many men because it is FDA-approved for male pattern hair loss, has extensive treatment experience, and clears more quickly. Better depends on the patient’s priorities, not efficacy alone.

What Did Ashton Kutcher Use for Hair Loss?

Ashton Kutcher has publicly discussed previously using dutasteride for hair loss. That is a celebrity anecdote, not clinical evidence.

His account cannot show how another person will respond. It does not control for diagnosis, dose, genetics, concurrent treatment, adherence, side effects, or the way results were assessed.

What Do Reddit Results Prove?

Reddit posts may raise useful questions, but they rarely prove efficacy. Dramatic successes and failures are more likely to be shared than ordinary stabilization, creating a distorted picture of typical outcomes.

When reviewing a transformation, check for:

  • Consistent lighting and camera angle
  • Similar hair length and styling
  • Wet versus dry hair
  • Treatment duration
  • Concurrent minoxidil or procedures
  • A confirmed diagnosis
  • Adherence information
  • Objective measurements
  • Side-effect disclosure

Anecdotes can help prepare questions for a clinician. They should not be used to copy a prescription regimen.

Are Tamsulosin or Spironolactone Substitutes?

Tamsulosin is an alpha-1 receptor blocker used for urinary symptoms associated with conditions such as BPH. It does not block DHT and is not a substitute for finasteride or dutasteride in hair-loss treatment.

Spironolactone is a different antiandrogen with distinct uses and safety considerations. It is not a like-for-like substitute, and its systemic antiandrogen effects require a separate clinical assessment.

Which Option Fits Your Next Clinical Conversation?

Bring a concise treatment record rather than relying on memory. Include:

  • The primary goal: preservation, regrowth, or both
  • Standardized baseline and follow-up photographs
  • Previous medication names, doses, and dates
  • Adherence and missed-dose patterns
  • Baseline sexual and mood symptoms
  • Current possible side effects
  • Fertility plans
  • Other prescriptions and supplements
  • Relevant medical and mental-health history
  • Budget and formulation preferences
  • Questions about oral versus topical exposure

The next step is not to copy the strongest-looking protocol. It is to connect the diagnosis, expected benefit, tolerability, reversibility, and monitoring in one coherent plan.

FAQ

Is Dutasteride Better Than Finasteride for Hair Loss?

Dutasteride often produces better average results in comparative studies because it blocks both type I and type II 5-alpha-reductase. Finasteride may still be a more appropriate first option because it is FDA-approved for male pattern hair loss and clears more quickly. Individual results cannot be predicted from potency alone.

Which Has Worse Side Effects: Finasteride or Dutasteride?

Neither medication is guaranteed to cause more severe side effects in every person. Their potential adverse effects overlap, but dutasteride suppresses DHT more broadly and remains in the body longer. That prolonged exposure matters when considering sexual function, mood, fertility, and reversibility.

How Long Should Finasteride Be Tried Before Considering Dutasteride?

Finasteride usually needs to be assessed over several months rather than weeks. The right review period depends on the diagnosis, consistency of use, tolerability, and objective evidence of progression. A clinician should also check for other causes of hair loss before recommending stronger DHT suppression.

Can Finasteride and Dutasteride Be Taken Together?

They should not be combined without explicit medical direction. Because both affect the same pathway and dutasteride persists for a long time, self-directed stacking can create overlapping exposure and make benefits or adverse effects harder to interpret.

What Are the Main Risks of Dutasteride?

Potential concerns include sexual or ejaculatory changes, changes in semen parameters, breast symptoms, mood symptoms, allergic reactions, pregnancy exposure, and effects on PSA interpretation. Its long half-life means exposure may continue well after treatment stops. A clinician should review individual risks before prescribing it.

Build a Hair Loss Plan Around Your Biology

Do not choose long-term medication solely because dutasteride sounds stronger or because one finasteride photo looks convincing. Start with a confirmed diagnosis, document your baseline, and build a clinician-led plan around treatment history, side-effect priorities, reproductive goals, and consistent monitoring.

Explore a personalized genetic and topical treatment assessment through Roots to replace guesswork with an evidence-led hair-loss plan.

Roots by Genetic Arts

19 Oct 2026

Resume Subscription

Your subscription is on hold because the last payment failed.
Would you like to renew your subscription and process the payment now?